Vidium Animal Health and Torigen Pharmaceuticals Partner to Increase Accessibility of Advanced Cancer Care for Canine Patients – Yahoo Finance

Animal health companies join forces to provide veterinarians across the country with more options for treating cancer in dogs
PHOENIX, Oct. 11, 2022 /PRNewswire-PRWeb/ — Vidium Animal Health announced today that it has partnered with Torigen Pharmaceuticals, an animal health biologics company, to offer genomic testing and precision medicine to more veterinarians. By opening up the use of personalized, precision medicine to the veterinary marketplace, Vidium and Torigen are providing specialists and general practicing veterinarians with more options to advance the care of dogs with cancer.
Vidium's genomic-based diagnostic products leverage the latest science available to provide critical information about a dog's cancer. The company's best-in-class genomic diagnostic test, SearchLight DNAⓇ, uses next-generation sequencing to identify important mutations in 120 relevant cancer genes. Knowing a tumor's genetic fingerprint can aid in the diagnosis and prognosis of cancer and inform treatment decisions. Vidium also offers a world-renowned specialty pathology team to support the diagnosis and treatment planning of diseases in small and large animals.
Torigen's expert sales team will now include SearchLight DNA alongside the company's personalized cancer immunotherapies in its precision medicine portfolio. When current treatment options aren't right for pets with cancer, Torigen offers a different solution. Using a portion of the patient's own tumor, Torigen's lab prepares a personalized vaccine, harnessing the patient's immune system to fight cancer.
Canine cancer care is becoming more accessible and precise with these diagnostic and therapeutic tools. Together with veterinarians all over the country, Vidium and Torigen are helping expand options for the pets we love.
"By leveraging the sales team at Torigen to provide veterinarians a suite of advanced precision cancer diagnostic tools, we can offer veterinary teams a unique combination of genomic, pathology, and oncology expertise to expand their options and help improve outcomes for their patients," comments David Haworth, DVM, PhD, President and Co-founder at Vidium.
"We are thrilled to be working with the team at Vidium," adds Ashley Kalinauskas, founder and CEO of Torigen. ""The combination of the company's diagnostic tests and precision medicine expertise coupled with our targeted cancer treatment will give veterinarians and their clients more cancer treatment options. I'm excited to leverage our specialty sales force to deliver value to veterinary clinics across the country."
ABOUT VIDIUM ANIMAL HEALTH:
Vidium Animal Health, a subsidiary of Translational Genomics Research Institute (TGen), is committed to advancing the understanding of disease to give pets the fullest lives possible. The company provides diagnostic tests to veterinary oncologists, general practitioners, and pet parents, and is passionate about unraveling the genetic components of common and complex diseases, including cancer. Vidium was built on a foundation of unimpeachable science and is led by a knowledgeable and experienced team with deep veterinary and clinical genomic roots. For more information, visit: vidiumah.com. Follow Vidium on Facebook, LinkedIn, and Twitter@vidiumah.
ABOUT TGEN, AN AFFILIATE OF CITY OF HOPE:
Based in Phoenix, Arizona, Translational Genomics Research Institute (TGen) is a nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes, and other life-threatening diseases: CityofHope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes, and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through the efficiency and effectiveness of the translational process. For more information, visit: tgen.org. Follow TGen on Facebook, LinkedIn, and Twitter @TGen.
ABOUT TORIGEN PHARMACEUTICALS:
Torigen is an animal health biologics company dedicated to helping pets with cancer and other unmet medical needs in veterinary medicine. With over 50% of all dogs over the age of 10 dying from cancer, Torigen is focused on providing affordable and accessible cancer care solutions for all companion animals. Torigen recognizes the instrumental role pets play in our families and is determined to extend the lives of companion animals despite a cancer diagnosis.
For more information about Torigen, please visit http://www.torigen.com. Follow Torigen on Facebook, LinkedIn, and Instagram.
Media Contact
John Kallassy, Torigen Pharmaceuticals, 860-519-9956, [email protected]
SOURCE Torigen Pharmaceuticals
Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly.
A month after detailing its strategic shift toward autoimmune diseases and cancer, Nimbus Therapeutics has captured the interest of a major pharmaceutical player.
Is Pfizer stock a sell on an expected decline for Covid vaccine sales in the third quarter? Is PFE stock now a sell?
Illustration by Luis G. Rendon/The Daily BeastAs the wave of COVID infections from the highly-contagious BA.5 subvariant finally subsided back in late July, new subvariants were already competing for dominance—and the opportunity to drive the next wave of infections.A little over two months later, epidemiologists are close to naming a winner. In the United Kingdom, infections from a highly mutated subvariant called BQ.1.1 are doubling every week—a rate of growth that far exceeds other leading su
If there is, it's wrong too — at least when applied to the stock market. As a case in point, here are three top biotech stocks that are defying the bear market. Few stocks in any sector have outperformed Vertex Pharmaceuticals (NASDAQ: VRTX) in 2022.
Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.
Recently, Biogen Inc (NASDAQ: BIIB) and Eisai Co (OTC: ESALY) announced encouraging data from the most-watched Alzheimer's therapies in the clinic. Lecanemab cleared accumulations in the brain of beta-amyloid, sticky protein fragments that researchers have long suspected contribute to Alzheimer's. Citing physicians and neurology researchers, Wall Street Journal reported that the drug's benefit to patients might be limited. They said the reduction of cognitive decline that patients experienced wa
(Bloomberg) — GSK Plc is free to hire a top dealmaker from AstraZeneca Plc after reaching an agreement with its rival, which had sued to block the sharing of sensitive information.Most Read from BloombergHere’s How Weird Things Are Getting in the Housing MarketThis Is What 7% Mortgages Will Do to the Housing MarketIt’s Official: The Fed’s in the RedThe Most Powerful Buyers in Treasuries Are All Bailing at OnceScreening Procedure Fails to Prevent Colon Cancer Deaths in Large StudyChris Sheldon w
After a failed attempt to broaden the use of its only approved drug, Rigel Pharmaceuticals Inc. will cut 30 jobs — about 16% of its workforce — to save as much as $8 million starting next year. The 200-employee South San Francisco company (NASDAQ: RIGL) made the move as it announced it will not seek Food and Drug Administration approval of its tablet drug fostamatinib based on a reanalysis of data from a late-stage clinical trial. The drug, sold as Tavalisse, is approved by the FDA for an excessive bruising and bleeding disorder known as immune thrombocytopenia, or ITP.
The Omicron spawn is slowly pushing back against a receding wave of BA.5 and is particularly widespread in the Midwest.
Since July of this year, 20 people across six states have been infected with the same strain of E. coli. Among them, five had to be hospitalized and one developed hemolytic uremic syndrome, known to cause kidney failure.No deaths have been reported, but this latest E. Coli outbreak has now sparked both a joint investigation by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), and product recalls from one of America's fastest-growing grocery retail c
The company hopes the drug, sotatercept, will help make up for revenue it will lose when the patent on a blockbuster cancer therapeutic expires at the end of this decade.
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
The benefits of colonoscopy in preventing colorectal cancer may have been exaggerated, according to a new study. Doctors in the U.S. say colon cancer screening does save lives.
After Uganda’s outbreak, the CDC urges doctors to be on alert for Ebola—also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF)—a rare but deadly virus.
The prevalence of preeclampsia, a life-threatening hypertensive disorder of pregnancy that features high blood pressure, is rising in South Florida, posing a threat to many mothers and infants. As a labor and delivery nurse at Memorial Hospital Miramar, part of Memorial Healthcare System, I work to raise awareness about the fact that we are treating more and more cases of preeclampsia in our system.
Is Merck stock a buy on positive results from a final-phase study in pulmonary arterial hypertension? Is MRK stock a buy right now?
Although Biogen and Eisai’s lecanemab cleared plaque from patients’ brains, researchers say the benefits may be limited.
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today it has successfully submitted, in collaboration with Prepaire, a grant application to the Office of Biomedical Advanced Research and Development Authority (BARDA), Division of Research, Innovation and Ventures (DRIVe).
15 those already on Medicare can make changes to their coverage as needed. This is known as the Medicare ​a​nnual ​e​nrollment period. Read: Sticking with your Medicare plan this open enrollment season?

source